Medtronic, Inc.

Onan Corporation

Mcgraw-edison Company

Mark S Lent

Kenneth Timothy Heruth

Carl D Wahlstrand

Keith Alan Miesel

Ruchika Singhal

Gregory F Molnar

Steven M Goetz

Gary William King

James Grant Skakoon

Xuan K Wei

Andrew J Ries

James M Olsen

Eric H Bonde

John E Kast

Robert M Skime

Jeffrey T Keacher

Andrew H Houchins

Michael J Schendel

Paul W Wacnik

Jordan J Greenberg

Justin A Blanco

Stephen M Clancey

Timothy J Denison

Eric J Panken

Darren A Janzig

Michael T Hegland

Jonathan C Werder

Dale F Seeley

Steven Streatfield Gill

David Anthnoy Simon

Steven R Christenson

Andrew N Csavoy

James E Cabak

Robert P Koziara

Daniel A Norrick

Eugene G Shanks

Thomas K Rose

Stanley E Data

Patrick A O'Gorman

Christopher M Hobot

Richard T Stone

Erik R Scott

Jamu Alford

James Martin Haase

William Jeffrey Bertrand

Reginald D Robinson

Maura G Donovan

Randall V Sparer

Christian Peclat

Chris C Christiansen

Thomas R Prentice

Paul H Plahn

John D Welter

James E Randall

William J Hooper

David A Overland

Laetitia Mayor

Gary A Salmonson

Michael C Miller

Paul W Haverly

Lothar Krinke

Paige R Nelson

Deborah A Klinkert

Stanely D Hjelmstad

Jim Olsen

Micheal Thomas Hegland

William H Monsen

Keith Ewer

Carl Wahstrand

Peripheral nerve field stimulation (PNFS) may be controlled based on detected physiological effects of the PNFS, which may be an efferent response to the PNFS. In some examples, a closed-loop therapy system may include a sensing module that senses a physiological parameter of the patient, which may be indicative of the patient's response to the PNFS. Based on a signal generated by the sensing module, the PNFS may be activated, deactivated or modified. Example physiological parameters of the patient include heart rate, respiratory rate, electrodermal activity, muscle activity, blood flow rate, sweat gland activity, pilomotor reflex, or thermal activity of the patient's body. In some examples, a patient pain state may be detected based on a signal generated by the sensing module, and therapy may be controlled based on the detection of the pain state.

Peripheral nerve field stimulation control

A system for use in managing a neuromodulation therapy includes an ultrasound transducer array controlled by a control unit to deliver ultrasound waveforms for causing modulation of neural tissue in a patient. The system acquires data indicating a response to the modulation, analyzes the acquired data to determine correlation data between a response to the modulation and an ultrasound control parameter, and reports the correlation data to enable identification of at least one therapy parameter to be used to deliver a neuromodulation therapy to the patient by a therapy delivery system.

Ultrasound diagnostic and therapy management system and associated method

Techniques for managing urinary or fecal incontinence include delivering a first type of therapy to generate a first physiological response and, upon detecting a trigger event, delivering a second type of therapy to generate a second physiological response. The first type of therapy can be delivered on a substantially regular basis, while the second type of therapy is delivered as needed to provide an additional boost of therapy. The trigger event for activating the delivery of the second type of therapy may include input from a sensor that indicates a bladder condition, patient activity level or patient posture, or patient input. In some examples, the therapy is stimulation therapy.

Incontinence therapy

A method and apparatus for optimizing a computer assisted procedure is provided. A method and apparatus for performing a procedure is also provided. Data can be accessed and processed to optimize and perform a procedure. The data can be augmented or supplemented with patient specific data.

Method and apparatus for optimizing a computer assisted surgical procedure

Implantable medical devices (IMDS) having anti-infective properties are described. Anti-infective agents are disposed in, on, or about at least a portion of a surface of the medical device. The anti-infective agents are disposed in or on a vehicle, which may be in the form of a coating layer or covering. The vehicle may be biodegradable so that, over time, the anti-infective agent is removed from a tissue location into which the device is implanted, reducing the likelihood that microorganisms resistant to the anti-infective agent will develop. IMDs having an anti-infective agent and an anti-activity agent disposed therein, thereabout, or thereon are also described. The anti-activity agent interferes with the activity of the anti-infective agent, may be released from a surface at the IMD at a time when activity of the anti-infective agent is no longer desired, and may reduce the likelihood that microorganisms resistant to the anti-infective agent will develop.

Anti-infective medical device

In an implantable medical device having individual modules, a coupling module couples the modules to one another. The coupling module supports electrical and/or mechanical coupling of the modules. The coupling module may assume a variety of shapes or configurations. The various embodiments of the coupling module may offer the modules varying degrees of freedom of movement relative to one another.

Coupling module of a modular implantable medical device

A movement state of a patient is detected based on brain signals, such as an electroencephalogram (EEG) signal. In some examples, a brain signal within a dorsal-lateral prefrontal cortex of a brain of the patient indicative of prospective movement of the patient may be sensed in order to detect the movement state. The movement state may include the brain state that indicates the patient is intending on initiating movement, initiating movement, attempting to initiate movement or is actually moving. In some examples, upon detecting the movement state, a movement disorder therapy is delivered to the patient. In some examples, the therapy delivery is deactivated upon detecting the patient is no longer in a movement state or that the patient has successfully initiated movement. In addition, in some examples, the movement state detected based on the brain signals may be confirmed based on a signal from a motion sensor.

Therapy control based on a patient movement state

Devices, systems and methods for delivering one or more drugs to one or more internal body locations (such as the cerebrospinal fluid) are disclosed. In various aspects, the systems and methods may involve catheters having infusion sections with permeable membranes and one or more tracking elements that may be used to place the infusions sections on the catheters in selected locations such as the spinal region.

Catheters with tracking elements and permeable membranes

Systems and methods for coordinated delivery of a therapeutic agent and low (less than about 20 Hz) and high (greater than about 50 Hz) frequency stimulation therapy are described. The systems include a control unit for coordinating therapy delivery between an infusion device and a pulse generator, such that a therapeutic agent is administered at a predetermined time relative to application of either low frequency or high frequency stimulation. For example, the control unit may instruct the infusion device to deliver therapeutic agent at a predetermined time prior to delivery of low frequency stimulation. Systems that include more than one infusion device or an infusion pump capable of delivering more than one therapeutic agent are also described.

Regional therapies for treatment of pain

Devices, systems and methods for delivering one or more drugs to one or more internal body locations (such as the cerebrospinal fluid) are disclosed. In various aspects, the systems and methods may involve catheters having infusion sections with permeable membranes that develop significant back pressure to enhance uniform delivery of the drug over an infusion section; catheters that have two or more infusion sections spaced apart along the length of the same catheter, catheters that include two or more infusion sections serviced by independent lumens (such that, e.g., different drug solutions can be delivered to the different infusion sections); implantable drug delivery systems with pumps and multiple reservoirs from which drugs can be delivered; systems that are capable of delivering drug solutions with selected densities; etc.

Implantable drug delivery systems and methods

Growing community of inventors

Brooklyn Park, MN, United States of America

Mark S Lent